Seeking Alpha

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute ...

SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NNVC) (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that ...
Seeking Alpha

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NNVC) (NYSE American:NNVC) (the "Company") today reported that it has received approval to Start Phase II Clinical ...

NanoViricides says NV-387 could address measles outbreaks as cases rise globally

NanoViricides (NYSE-A:NNVC) said on Tuesday its antiviral drug candidate NV-387 could help address rising measles cases ...
USA Today

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

SHELTON, CONNECTICUT / ACCESS Newswire / December 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the ...
Charlotte Observer

Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the ...
The Indianapolis Star

NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave – NV-387 is Effective Against H3N2

SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs ...
USA Today

Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

According to the US FDA (https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products). “NV ...